Drugs / IGT-303
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07231679 | Oct 2025 → Oct 2026 expected | chronic kidney disease | Ingenia Therapeutics INC | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | IGT-303 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07231679 ↗ |
| Route | Intravenous | “IGT-303 administered via IV or SC” NCT07231679 ↗ |
| Route | Subcutaneous | “IGT-303 administered via IV or SC” NCT07231679 ↗ |